Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Initiates Coverage On Silence Therapeutics with Outperform Rating, Announces Price Target of $67

Author: Benzinga Newsdesk | January 31, 2024 07:00am
BMO Capital analyst Kostas Biliouris initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Outperform rating and announces Price Target of $67.

Posted In: SLN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist